Prescription drug monitoring program data tracking of opioid addiction treatment outcomes in integrated dual diagnosis care involving injectable naltrexone

dc.contributor.authorSajid, Ayesha
dc.contributor.authorWhiteman, Aaron
dc.contributor.authorBell, Richard L.
dc.contributor.authorGreene, Marion S.
dc.contributor.authorEngleman, Eric A.
dc.contributor.authorChambers, R. Andrew
dc.contributor.departmentDepartment of Psychiatry, IU School of Medicineen_US
dc.date.accessioned2017-08-11T20:46:23Z
dc.date.available2017-08-11T20:46:23Z
dc.date.issued2016-10
dc.description.abstractBACKGROUND AND OBJECTIVES: Fourfold increases in opioid prescribing and dispensations over 2 decades in the U.S. has paralleled increases in opioid addictions and overdoses, requiring new preventative, diagnostic, and treatment strategies. This study examines Prescription Drug Monitoring Program (PDMP) tracking as a novel measure of opioid addiction treatment outcomes in a university-affiliated integrated mental health-addiction treatment clinic. METHODS: Repeated measure parametrics examined PDMP and urine drug screening (UDS) data before and after first injection for all patients (N = 68) who received at least one long-acting naltrexone injection (380 mg/IM) according to diagnostic groupings of having either (i) alcohol (control); (ii) opioid; or (iii) combined alcohol and opioid use disorders. RESULTS: There were no group differences post-injection in treatment days, injections delivered, or treatment service encounters. UDS and PDMP measures of opioid exposures were greater in opioid compared to alcohol-only patients. Post-first injection, UDS's positive for opioids declined (p < .05) along with PDMP measures of opioid prescriptions (p < .001), doses (p < .01), types (p < .001), numbers of dispensing prescribers (p < .001) and pharmacies (p < .001). Opioid patients without alcohol disorders showed the best outcomes with 50% to 80% reductions in PDMP-measures of opioids, down to levels of alcohol-only patients. CONCLUSIONS: This study shows PDMP utility for measuring opioid addiction treatment outcomes, supporting the routine use of PDMPs in clinical and research settings. SCIENTIFIC SIGNIFICANCE: These findings demonstrate that opioid addiction in patients with complex addictions and mental illnesses comorbidities can show effective treatment responses as measured by PDMP tracking of decreases in opioid prescriptions to those patients. (Am J Addict 2016;25:557-564).en_US
dc.eprint.versionFinal published versionen_US
dc.identifier.citationSajid, A., Whiteman, A., Bell, R. L., Greene, M. S., Engleman, E. A., & Chambers, R. A. (2016). Prescription drug monitoring program data tracking of opioid addiction treatment outcomes in integrated dual diagnosis care involving injectable naltrexone. The American Journal on Addictions, 25(7), 557–564. http://doi.org/10.1111/ajad.12441en_US
dc.identifier.issn1521-0391en_US
dc.identifier.urihttps://hdl.handle.net/1805/13810
dc.language.isoen_USen_US
dc.publisherWiley Blackwell (Blackwell Publishing)en_US
dc.relation.isversionof10.1111/ajad.12441en_US
dc.relation.journalThe American Journal on Addictionsen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/3.0/us
dc.sourcePMCen_US
dc.subjectPDMP trackingen_US
dc.subjectopiod addiction treatmenten_US
dc.subjectopiod prescriptionsen_US
dc.titlePrescription drug monitoring program data tracking of opioid addiction treatment outcomes in integrated dual diagnosis care involving injectable naltrexoneen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
AJAD-25-557.pdf
Size:
247.97 KB
Format:
Adobe Portable Document Format
Description:
Final published version
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.88 KB
Format:
Item-specific license agreed upon to submission
Description: